Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News ENDO INTERNATIONAL PLC ENDPQ

Healthcare Drug Manufacturers - Specialty & Generic
Endo International plc has filed a voluntary petition under Chapter 11 of the U.S. Bankruptcy Code and is winding down its business. The Company has no business operations.

Recent & Breaking News (GREY:ENDPQ)

Endo Reports First Quarter Financial Results

PR Newswire May 1, 2014

Endo Health Solutions Inc. Announces Extension of Expiration Date and Reopening of Withdrawal Rights in Exchange Offers for its 7% Senior Notes due 2019, 7.00% Senior Notes due 2020 and 7 1/4% Senior Notes due 2022

PR Newswire April 30, 2014

Endo Reaches Agreements in Principle to Settle a Substantial Majority of AMS Litigation Cases

PR Newswire April 30, 2014

Endo Health Solutions Inc. Announces Extension of Expiration Date in Exchange Offers for its 7% Senior Notes due 2019, 7.00% Senior Notes due 2020 and 7 1/4% Senior Notes due 2022

PR Newswire April 30, 2014

Endo to Acquire Specialty Pharmaceuticals Company Somar

PR Newswire April 29, 2014

Endo Appoints Dr. Hemanth J. Varghese as Executive Vice President of Corporate Development and Strategy

PR Newswire April 28, 2014

Endo Acquires Rights to Sumavel® DosePro®

PR Newswire April 24, 2014

Endo Health Solutions Inc. Announces Receipt of Requisite Tenders and Consents in the Exchange Offers and Consent Solicitations Relating to its 7% Senior Notes due 2019, 7.00% Senior Notes due 2020 and 7¼% Senior Notes due 2022

PR Newswire April 17, 2014

Endo to Announce First Quarter 2014 Financial Results on May 1, 2014

PR Newswire April 15, 2014

Endo Health Solutions Inc. Amends Exchange Offers and Consent Solicitations for its 7% Senior Notes due 2019, 7.00% Senior Notes due 2020 and 7 1/4% Senior Notes due 2022

PR Newswire April 14, 2014

Endo Health Solutions Inc. Announces Extension of Consent Date and Expiration Date in Exchange Offers and Consent Solicitations for its 7% Senior Notes due 2019, 7.00% Senior Notes due 2020 and 7-1/4% Senior Notes due 2022

PR Newswire April 11, 2014

Ampio Pharmaceuticals' Vyrix Enters into an Agreement with Paladin Labs for Exclusive Rights to Zertane(TM) in Canada and Other Territories to Broaden its International Footprint

PR Newswire April 10, 2014

Louis Van Amstel, Former Dancing with the Stars Professional, Joins "Making Your Move" Campaign to Raise Awareness of Osteoarthritis

PR Newswire April 9, 2014

Endo Health Solutions Inc. Amends Exchange Offers and Consent Solicitations for its 7% Senior Notes due 2019, 7.00% Senior Notes due 2020 and 7 1/4% Senior Notes due 2022

PR Newswire April 8, 2014

Endo International plc Announces Endo Health Solutions Inc. Will Commence Exchange Offers

PR Newswire March 28, 2014

Endo Announces Appointment of Dr. Susan Hall as New Chief Scientific Officer and Global Head of R&D and Quality

Canada NewsWire March 7, 2014

U.S. FDA Approves AVEED(TM) (Testosterone Undecanoate) Injectable Testosterone Replacement Therapy For Men Living With Hypogonadism, Or Low-T

PR Newswire March 6, 2014